Individualized therapy for hypertension [1]

Hypertension

Volumn 47, Issue 3, 2006, Pages

  Spence, J David ^a  

^a Stroke Prevention and Atherosclerosis Research Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMILORIDE; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; SPIRONOLACTONE;

ANTIHYPERTENSIVE ACTIVITY; HIGH RISK PATIENT; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; INDIVIDUALIZATION; LETTER; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; ETHNOLOGY;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION;

EID: 33644984788     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000203771.24792.bf     Document Type: Letter

References (6)

1. Frazier L, Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. Pharmacogenomics J. 2004;4:17-23.
2. Spence JD. Physiologic tailoring of therapy for resistant hypertension: 20 years' experience with stimulated renin profiling. Am J Hypertens. 1999;12:1077-1083.
3. Eide IK, Torjesen PA, Drolsum A, Bobovic A, Lilledahl NP. Low renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22:2217-2226.
4. Grim CE, Cowley AW Jr, Hamet P, Gaudet D, Kaldunski ML, Kotchen JM, Krishnaswami S, Pausova Z, Roman R, Tremblay J, Kotchen TA. Hyperaldosteronism and hypertension, ethnic differences. Hypertension. 2005;45:766-772.
5. Spence JD. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens. 2004;22:2038-2039.
6. Baker EH, Duggal A, Dong Y, Ireson NJ, Wood M, Markandu ND, MacGregor GA. Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension. 2002;40:13-17.